Has Jason Hanson, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,713 in general payments to Jason Hanson, MD across 146 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jason Hanson, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jason Hanson, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jason Hanson, MD

Otolaryngology · Bridgeton, MONPI 1063522597

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 146 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $903, more than ten times the $66 reported in 2019.

$2,713in general payments, 2019–2025

Across 146 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Regeneron Healthcare Solutions, Inc.$421
Inspire Medical Systems, Inc.$401
GSK$386
Optinose US, Inc.$299
Pfizer$244
Teva Pharmaceuticals USA, Inc.$160
plus $802 from 17 others

What the payments were for

Food & beverage$2,713100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Regeneron Healthcare Solutions, Inc.	20	$421
Inspire Medical Systems, Inc.	11	$401
GSK	22	$386
Optinose US, Inc.	25	$299
Pfizer	19	$244
Teva Pharmaceuticals USA, Inc.	9	$160
Sanofi	8	$160
Integra Lifesciences Corporation	2	$80
Itamar Medical Inc	2	$78
Biohaven Pharmaceutical Holding Company Ltd.	4	$59
Acclarent, Inc	2	$58
Johnson & Johnson	2	$57
Amgen	4	$56
Novartis	3	$44
AstraZeneca	2	$38
Biohaven Pharmaceuticals, Inc.	2	$35
Smith+Nephew	2	$31
Hikma Pharmaceuticals USA	2	$27
Aerin Medical Inc.	1	$21
Ironshore Pharmaceuticals Inc.	1	$17
Kowa Pharmaceuticals America, Inc.	1	$15
Davol Inc.	1	$14
Phathom Pharmaceuticals, Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Inspire$137

How this compares

$2,713 in reported general payments places this provider in the 75th percentile of 210 otolaryngology providers in Missouri.

See all otolaryngology providers in Missouri →

Medicare billing

Part B allowed, 2024

$125,278

Medicare patients

505

Services billed

1,193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Famotidine	409	$6,379
Ipratropium Bromide	96	$3,609
Azelastine Hcl	100	$2,358
Fluocinonide	104	$2,032
Fluticasone Propionate	98	$1,971
Omeprazole	167	$1,879
Gentamicin Sulfate	138	$1,843
Pilocarpine Hcl	11	$1,373
Tobramycin-DexamethasoneTobramycin/Dexamethasone	21	$1,345
CefuroximeCefuroxime Axetil	66	$1,032
Doxycycline Monohydrate	53	$946
Doxycycline Hyclate	22	$390
Pantoprazole Sodium	21	$344
Cefdinir	21	$338
Nortriptyline Hcl	17	$337

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Bridgeton

Jonathan LusardiBridgeton$5K
Talon ManingasJoplin$314K
Ryan JacksonSaint Louis$284K
Ravindra UppaluriSaint Louis$168K
James GouldFestus$143K
John SchneiderSaint Louis$74K
Amit WaliaSaint Louis$21K
Bharat PanugantiSaint Louis$19K
Jeffrey SharonSt. Louis$18K
Kelvin WallsLees Summit$14K

See the full list for Missouri →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →